ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0619

Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons

Selina Ohl1, Klaus Frommer2, Markus Rickert3, Stefan Rehart4, Ulf Müller-Ladner5 and Elena Neumann6, 1Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, 2Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, 3Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, 4Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, 5JLU Campus KK, Bad Nauheim, Germany, 6JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany

Meeting: ACR Convergence 2022

Keywords: Inflammation, rheumatoid arthritis, Synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there are various treatment options, RA cannot yet be cured. Therefore, remission is the therapeutic goal. Since the prognostic outcomes of patients in remission vary widely, a better understanding of remission is necessary.
The objective is the characterization of remission in RA by comparison of histological and molecular features in the synovium of patients in remission and those with an active disease.

Methods: RA patients (age 43-81 years, mean 62.2 years) receiving joint replacement surgery were categorized into remission vs. active disease based on clinical (e.g. painful joints, pain degree, medication) and laboratory parameters (e.g. ESR, CRP, leucocytes). To characterize histologically the type and grade of synovitis, the Krenn Score was applied. RA synovial fibroblasts (RASF) of patients in remission and those with an active disease were either stimulated with IL-1 or unstimulated for 24 h in passage 3 followed by RNA sequencing to further characterize remission on RNA level. Evaluation included analysis of differentially expressed genes (DEG) based on a combination of absolute expression, divergence and significance as well as gene set enrichment analysis of the DEGs in order to identify the enriched gene sets or pathways.

Results: Clinical classification of 39 synovial tissues led to the inclusion of 20 active patients and 19 in remission. Patients in remission showed lower synovitis scores. Specifically hyperplasia (P=0.021) and total Krenn score (P=0.022) showed significant differences for patients in remission compared to active disease. Sub-analyses regarding medication (e.g. biologicals, DMARDs, NSAIDs, glucocorticoids) confirmed the observations between remission and active RA for all drugs and indicated an overall reduction of hyperplasia. Especially patients receiving biologics showed a 4.2 fold decrease of hyperplasia in remission. The results of the RNA sequencing indicated homogeneity of the expressed genes and the undergoing pathways between the RASF of patients in remission and those with an active RA. These observations were evident in both, the unstimulated approaches, and the RASF stimulated with IL-1. However, RNAseq identified several differentially expressed genes. These genes include IL-36B (-2.85 fold), cathepsin K (-0.73 fold) and folliculin (active vs. remission: -0.62 fold) which were downregulated in remission and play a crucial role in the progression of RA.

Conclusion: The characterization of synovium after joint replacement surgery was used to compare histological and molecular differences that may help to characterize remission in RA. The histology showed a lower degree of inflammation and, most prominent, hyperplasia for patients in remission, specifically in patients receiving biologics. RNAseq identified several genes showing altered expressions related to the pro-inflammatory and destructive processes during RA which gives insight into the molecular characteristics of remission.


Disclosures: S. Ohl, None; K. Frommer, None; M. Rickert, None; S. Rehart, None; U. Müller-Ladner, Biogen; E. Neumann, None.

To cite this abstract in AMA style:

Ohl S, Frommer K, Rickert M, Rehart S, Müller-Ladner U, Neumann E. Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/differences-between-patients-in-remission-with-active-rheumatoid-arthritis-by-histological-and-molecular-comparisons/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-between-patients-in-remission-with-active-rheumatoid-arthritis-by-histological-and-molecular-comparisons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology